Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin).
Toray Industries Inc. has developed an endotoxin removal cartridge (Toraymyxin) composed of a polymyxin B immobilized, fibrous adsorbent. Toraymyxin has been listed as a blood purification medical device for endotoxin removal to be reimbursed by the Japanese national health insurance since 1994. Toraymyxin can be applied to patients with endotoxemia or suspected gram-negative infection, which fulfilll the conditions of Systemic Inflammatory Response Syndrome (SIRS) and have septic shock demanding vasopressor infusion. Since 1994, over 30,000 patients have received this treatment. The safety of this device has been confirmed and improvement of hemodynamic dysfunction has been shown to be a major benefit. Infection resulting from an acute abdominal condition requiring surgery has been shown to be one of the good indications for Toraymyxin. Further studies are now ongoing to establish Toraymyxin treatment as one of the options to treat sepsis and septic shock patients and to clarify the mechanisms involved in this therapy.
Shoji
Hisataka
H
Division of Planning and Science, Department of Blood Purification Medical Devices, Toray Medical Co., Tokyo, Japan. Hisataka_Shoji@tmc.toray.co.jp
D000327:Adsorption; D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004285:Dogs; D019446:Endotoxemia / Q000401:mortality / Q000628:therapy; D004731:Endotoxins / Q000009:adverse effects*; D006464:Hemoperfusion / Q000295:instrumentation* / Q000379:methods; D006801:Humans; D015337:Multicenter Studies as Topic; D011112:Polymyxin B / Q000737:chemistry* / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D012772:Shock, Septic / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D004731:Endotoxins; D011112:Polymyxin B